SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Coleman M, Babb P, Harris S, Quinn M, Sloggett A, De Stavola B. Report: Cancer survival in England and Wales, 1991–98. Office for National Statistics, Health Statistics Q 2000; 6: 7180
  • 2
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. Ca J Clin 2000; 50: 733
  • 3
    Lum BL, Torti FM. Adjuvant intravesicular pharmacotherapy for superficial bladder cancer. J Nat Cancer Inst 1991; 83: 68294
  • 4
    Duque JL, Loughlin KR. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy. Urol Clin North Am 2000; 27: 12535
  • 5
    Jauhiainen K, Alfthan O. Instillation of mitomycin C and doxorubicin in the prevention of recurrent superficial (Ta–T1) bladder cancer. Br J Urol 1987; 60: 549
  • 6
    Heney NM, Koontz WW, Barton B et al. Intravesical thiotepa versus mitomycin C in patients with Ta, T1 and TIS transitional cell carcinoma of the bladder: a phase III prospective randomized study. J Urol 1988; 140: 13903
  • 7
    Da Silva FC, Ferrito F, Brandao T, Santos A. 4′-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer. European Urol 1992; 21: 424
  • 8
    Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976; 116: 1803
  • 9
    Lamm DL. Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 1985; 134: 407
  • 10
    Herr H. Current results, natural history and implications for urothelial cancer prevention. J Cell Biol Suppl 1992; 161: 1129
  • 11
    Herr HW, Schwalb DM, Zhang ZF et al. Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial. J Clin Oncol 1995; 13: 14048
  • 12
    Shelley MD, Kynaston H, Court J et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001; 88: 20916
  • 13
    Smith JA Jr, Labasky RF, Cockett AT, Fracchia JA, Montie JE, Rowland RG. Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 and TIS). The American Urological Association. J Urol 1997; 162: 1697701
  • 14
    DeBruyne FM, Van Der Meijden AP, Geboers AD et al. BCG (RIVM) versus mitomycin intravesical therapy in superficial bladder cancer. First results of randomized prospective trial. Urology 1988; 31 (Suppl. 3): 205
  • 15
    Hall RR, Parmar MK, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. Br Med J 1994; 308: 25760
  • 16
    Kurth KH, Denis L, Bouffioux C et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 1995; 11: 31
  • 17
    Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998; 17: 281534
  • 18
    Krege S, Giani G, Meyer R, Otto T, Rubben H. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics. J Urol 1996; 156: 9626
  • 19
    Malmstrom PU, Wijkstrom H, Lundholm C, Wester K, Busch C, Norlen BJ. 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999; 161: 11247
  • 20
    Lamm D, Blumenstein B, Crawford D et al. Randomised intergroup comparison of bacillus Calmette-Guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder. Urol Oncol 1995; 1: 11926
  • 21
    Rintala E, Jauhiainen K, Alfthan O et al. Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guerin) in superficial bladder cancer. Eur Urol 1991; 20: 1925
  • 22
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guerin-Tice versus bacillus Calmette-Guerin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urology Group. Semin Urol Oncol 1996; 14 (Suppl. 1): 106
  • 23
    Witjes JA, Van Der Meijden AP, Collette L, Sylvester R, Debruyne FM, Van Aubel A, Witjes WP. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 1998; 52: 40310
  • 24
    Nogueira March J, Solsona E, Unda M et al. A multicenter and randomised prospective study comparing three intravesical therapies, two with bacillus Calmette-Guerin and one with mitomycin C chemotherapy in medium and low risk bladder tumours. Eur Urol 2001; 39 (Suppl. 5): Abs 119
  • 25
    Pawinski A, Sylvester R, Kurth KH et al. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 1996; 156: 193440
  • 26
    Bohle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer. a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 905
  • 27
    Sylvester RJ, Van Der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 196470
  • 28
    Kilbridge KL, Kantoff P. Intravesical therapy for superficial bladder cancer: is it a wash? J Clin Oncol 1994; 12: 14
  • 29
    Al-Sukhun S, Hussain M. Current understanding of the biology of advanced bladder cancer. Cancer 2003; 97 (Suppl. 8): 206475
  • 30
    Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL. Penetration of mitomycin C in human bladder. Cancer Res 1993; 53: 331420
  • 31
    Hayes MC, Birch BR, Cooper AJ, Primrose JN. Cellular resistance to mitomycin C is associated with overexpression of MDR-1 in a urothelial cancer cell line (MGH-U1). BJU Int 2001; 87: 24550
  • 32
    Xu BH, Gupta V, Singh SV. Mitomycin C sensitivity in human bladder cancer cells: possible role of glutathione and glutathione transferase in resistance. Arch Biochem Biophys 1994; 308: 16470
  • 33
    Lynn NN, Howe MC, Hale RJ, Collins GN, O'Reilly PH. Over expression of metallothionein predicts resistance of transitional cell carcinoma of bladder to intravesical mitomycin therapy. J Urol 2003; 169: 7213
  • 34
    Kuroda K, Brown EJ, Telle WB, Russell DG, Ratliff TL. Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest 1993; 91: 6976